Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity.
Phase of Trial: Phase IV
Latest Information Update: 08 Feb 2013
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors Allergopharma
- 18 Nov 2006 New trial record.